Arrowhead Presents New Phase 2 Data on Plozasiran and Zodasiran at AHA 2023
- Plozasiran achieved mean max reductions of up to 90% in APOC3 and 87% in triglycerides in patients with severe hypertriglyceridemia - In patients with mixed dyslipidemia, mean max reduction in...